Skip to main content
. 2023 Jun 22;2023(6):CD001423. doi: 10.1002/14651858.CD001423.pub4

Emili 1983.

Methods Single‐site study
Randomization: noted, but method not stated
Blinding: participants, providers
Participants Geographic region: Italy
Study setting: community
N = 30
Baseline symptom score: NR
Baseline prostate volume: NR
Mean age (range): NR (44 to 78) years
Race: white
Diagnostic criteria: men with manageable BPH
Interventions Control: matching placebo
Treatment: Permixon 160 mg twice daily
Study duration: 4 weeks
Lost to follow‐up: n = 0
Outcomes Peak urine flow
Mean urine flow
Bladder residual volume
Prostate size (qualitative scale used)
Nocturia
Dropouts due to side effects: none
Notes Exclusions: prior treatment for BPH
Full text not available for this update.